Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AFIB

AFIB - Acutus Medical, Inc. Stock Price, Fair Value and News

0.23USD-0.01 (-4.17%)Delayed as of 21 Feb 2024, 12:59 pm ET
Watchlist

Market Summary

USD0.23-0.01
Delayedas of 21 Feb 2024, 12:59 pm
-4.17%

AFIB Stock Price

View Fullscreen

AFIB RSI Chart

AFIB Valuation

Market Cap

7.0M

Price/Earnings (Trailing)

-0.21

Price/Sales (Trailing)

0.36

EV/EBITDA

-0.79

Price/Free Cashflow

-0.12

AFIB Price/Sales (Trailing)

AFIB Profitability

EBT Margin

-166.00%

Return on Equity

-103.42%

Return on Assets

-38.7%

Free Cashflow Yield

-866.65%

AFIB Fundamentals

AFIB Revenue

Revenue (TTM)

19.7M

Rev. Growth (Yr)

43.74%

Rev. Growth (Qtr)

-0.96%

AFIB Earnings

Earnings (TTM)

-32.8M

Earnings Growth (Yr)

35.19%

Earnings Growth (Qtr)

27.85%

Breaking Down AFIB Revenue

52 Week Range

0.231.59
(Low)(High)

Last 7 days

5.3%

Last 30 days

5.3%

Last 90 days

-20%

Trailing 12 Months

-86.8%

How does AFIB drawdown profile look like?

AFIB Financial Health

Current Ratio

4.92

Debt/Equity

1.1

Debt/Cashflow

-1.67

AFIB Investor Care

Shares Dilution (1Y)

2.99%

Diluted EPS (TTM)

-1.1

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202316.9M18.1M19.7M0
202217.4M16.7M15.8M16.4M
202110.5M14.0M15.5M17.3M
20204.2M5.7M7.1M8.5M
20190002.8M

Tracking the Latest Insider Buys and Sells of Acutus Medical, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 06, 2024
sohn tom
sold (taxes)
-1,311
0.173
-7,582
svp, gen. counsel & secretary
Feb 01, 2024
sohn tom
sold (taxes)
-1,090
0.191
-5,709
svp, gen. counsel & secretary
Feb 01, 2024
mukai takeo
sold (taxes)
-547
0.191
-2,869
cfo
Jan 07, 2024
roman david
sold (taxes)
-4,552
0.189
-24,086
president & ceo
Jan 07, 2024
mathews kevin
sold (taxes)
-1,198
0.189
-6,342
svp, commercial
Sep 01, 2023
mukai takeo
sold (taxes)
-843
0.488
-1,729
cfo
Aug 05, 2023
sohn tom
sold (taxes)
-298
0.69
-433
svp, gen. counsel & secretary
Aug 05, 2023
mathews kevin
sold (taxes)
-92.46
0.69
-134
svp, commercial
Aug 02, 2023
mukai takeo
sold (taxes)
-
-
-501
cfo
Aug 01, 2023
roman david
sold (taxes)
-
-
-6,484
president & ceo

1–10 of 50

Which funds bought or sold AFIB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 14, 2024
STATE STREET CORP
unchanged
-
-25,660
10,473
-%
Feb 14, 2024
CITADEL ADVISORS LLC
new
-
21,739
21,739
-%
Feb 14, 2024
Royal Bank of Canada
added
72.81
-
-
-%
Feb 14, 2024
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
unchanged
-
-1,316,300
537,217
0.01%
Feb 14, 2024
VANGUARD GROUP INC
reduced
-74.92
-736,855
57,761
-%
Feb 14, 2024
ORBIMED ADVISORS LLC
unchanged
-
-1,310,160
534,709
0.01%
Feb 14, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
sold off
-100
-55,380
-
-%

1–10 of 43

Are Funds Buying or Selling AFIB?

Are funds buying AFIB calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AFIB
No. of Funds

Unveiling Acutus Medical, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Nov 13, 2023
flynn james e
5.54%
5,731,096
SC 13D/A
Feb 13, 2023
capital world investors
2.8%
797,523
SC 13G/A
Jul 05, 2022
flynn james e
5.72%
5,731,096
SC 13D/A
Apr 27, 2022
flynn james e
5.74%
3,841,587
SC 13D/A
Feb 14, 2022
advent life sciences llp
5.8%
1,617,149
SC 13G/A
Feb 11, 2022
kerrisdale advisers, llc
0%
0
SC 13G/A
Feb 11, 2022
capital world investors
5.7%
1,600,000
SC 13G
Nov 18, 2021
orbimed advisors llc
9.5%
2,648,386
SC 13D/A
Aug 31, 2021
orbimed advisors llc
7.7%
6,881,953
SC 13D/A
Aug 26, 2021
flynn james e
5.81%
3,841,587
SC 13D/A

Recent SEC filings of Acutus Medical, Inc.

View All Filings
Date Filed Form Type Document
Feb 08, 2024
8-K
Current Report
Feb 07, 2024
4
Insider Trading
Feb 02, 2024
4
Insider Trading
Feb 02, 2024
4
Insider Trading
Jan 18, 2024
4
Insider Trading
Jan 18, 2024
4
Insider Trading
Jan 17, 2024
8-K
Current Report
Jan 11, 2024
8-K
Current Report
Nov 14, 2023
10-Q
Quarterly Report
Nov 13, 2023
SC 13D/A
13D - Major Acquisition

Peers (Alternatives to Acutus Medical, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
203.0B
40.1B
0.08% 5.41%
35.47
5.06
-8.12% -17.45%
69.5B
19.5B
1.90% -2.48%
55.36
3.57
4.02% -22.04%
24.0B
3.8B
13.67% -2.23%
66.19
6.31
-1.48% -28.97%
21.2B
14.9B
3.05% 1.38%
7.99
1.42
2.01% 209.17%
MID-CAP
10.1B
2.7B
6.89% -27.73%
-15.83
3.78
-4.68% 82.43%
9.8B
12.7B
2.56% -12.12%
22.09
0.77
0.68% -30.25%
9.2B
3.5B
8.76% 25.90%
32.42
2.64
4.97% 18.89%
7.2B
3.9B
-8.15% -6.44%
-32.65
1.82
-2.62% 73.16%
3.4B
342.6M
-1.40% 20.18%
-286.99
10.05
42.19% 84.12%
2.6B
6.6B
-4.32% -4.67%
13.17
0.4
2.61% 0.52%
SMALL-CAP
987.5M
3.1B
8.08% -63.68%
-2.32
0.32
7.95% -543.98%
355.0M
163.3M
8.18% -20.52%
-14.45
2.17
7.14% -56.09%
241.9M
329.5M
3.17% -52.24%
-17.14
0.73
0.49% 64.22%
74.8M
50.3M
4.50% -30.54%
-4.94
1.49
3.23% 20.81%
4.3M
3.7M
-15.66% 215.09%
-0.35
1.15
5.77% 8.23%

Acutus Medical, Inc. News

Latest updates
Marketscreener.com08 Feb 202409:34 pm

Acutus Medical, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q2
Revenue-1.0%5,238,0005,289,0004,170,0004,962,0003,644,0004,076,0003,681,0004,362,0004,601,0004,709,0003,591,0002,574,0003,173,0001,134,0001,583,0001,114,500646,000734,000
Gross Profit-21.0%-3,357,000-2,774,000-2,620,000--3,307,000-5,621,000-3,260,000-----------
Operating Expenses-33.5%9,579,00014,397,00014,687,00011,727,00017,154,000-20,549,00035,370,00034,262,00031,690,00032,009,00031,424,00030,580,00029,435,00020,599,00019,183,000-31,810,00014,609,000
  S&GA Expenses-19.9%7,432,0009,284,0009,565,0009,447,0009,679,00014,143,00014,385,00015,865,00015,805,00015,601,00016,252,00015,164,00015,833,0009,125,00010,235,000-7,978,0006,927,000
  R&D Expenses-29.5%4,795,0006,799,0006,117,0006,269,0005,946,0007,935,0008,003,0008,840,0009,299,0009,174,0009,370,0008,962,0008,343,0008,176,0007,973,0007,540,0005,865,0005,247,000
EBITDA Margin30.2%-1.13-1.62-0.30-1.73-4.73-4.92-6.72-6.15-6.78-7.72-9.93-11.07-10.27-----
Interest Expenses1.0%1,409,0001,395,0001,307,0001,290,0001,109,0001,290,0001,411,0001,415,0001,441,0001,456,0001,388,0001,416,0001,366,0001,370,0001,354,000-1,394,00013,769,000
Income Taxes-75,000--82,000-------23,000------
Earnings Before Taxes28.3%-13,162,000-18,346,000-16,315,00015,190,000-20,425,0005,718,000-40,017,000-31,264,000-28,511,000-28,727,000-29,181,000-29,379,000-31,288,000-23,193,000-18,098,000---
EBT Margin24.8%-1.66-2.21-0.94-2.42-5.46-5.63-7.41-6.82-7.48-8.44-10.79-12.05-13.75-----
Net Income27.8%-13,237,000-18,346,000-16,315,00015,108,000-20,425,0005,718,000-40,017,000-31,264,000-28,511,000-28,727,000-29,181,000-29,421,000-31,288,000-23,193,000-18,098,000--32,085,000-30,345,000
Net Income Margin24.6%-1.67-2.21-0.94-2.42-5.46-5.63-7.41-6.82-7.49-8.44-10.80-12.05-13.75-----
Free Cashflow6.1%-14,410,000-15,352,000-16,732,000-14,457,000-22,108,000-23,730,000-28,688,000-25,986,000-27,931,000-25,763,000-29,993,000-27,534,000-29,654,000-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Assets-15.5%85.0010011613311513813217019714116219321372.0089.00105
  Current Assets-16.8%73.0087.0010211894.0011610412615610211615117646.00-82.00
    Cash Equivalents4.5%24.0023.0023.0026.0032.0051.0012.0024.0059.007.009.0025.0058.0024.0021.0010.00
  Inventory0.4%16.0016.0015.0013.0015.0015.0018.0016.0015.0015.0014.0013.0011.0012.00-8.00
  Net PPE-8.8%7.007.008.009.0010.0011.0013.0014.0015.0015.0015.0012.0010.008.00-4.00
  Goodwill--------12.0012.0012.0012.0012.0012.0012.00-12.00
Liabilities-6.2%53.0057.0056.0058.0057.0062.0063.0064.0064.0065.0062.0066.0060.0075.0077.0078.00
  Current Liabilities-19.0%15.0018.0017.0020.0018.0023.0017.0019.0018.0018.0018.0022.0016.0031.00-32.00
  Long Term Debt0.4%35.0035.0035.0034.0034.0034.0041.0040.0040.0040.0039.0039.0039.0039.00-38.00
    LT Debt, Non Current0.4%35.0035.0035.0034.0034.0034.0041.0040.0040.0040.0039.0039.0039.0039.00-38.00
Shareholder's Equity-27.5%32.0044.0060.0075.0058.0077.0069.0010613476.001001271530.000.000.00
  Retained Earnings-2.4%-566-552-534-518-533-513-518-478-447-418-390-361-331-300--259
  Additional Paid-In Capital0.2%59959859659459259058858558149549048748436.00-33.00
Shares Outstanding0.3%29.0029.0029.0029.0028.0028.0028.0028.0029.0028.0028.0028.006.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q2
Cashflow From Operations4.1%-14,000-14,600-16,500-12,947-21,353-23,100-27,600-22,600-27,185-23,615-26,300-24,131-26,277-17,203-17,558---
  Share Based Compensation-26.3%1,2781,7341,9041,8941,8842,5813,0323,4913,5773,7762,9102,8316,3741,1571,741-812803
Cashflow From Investing12.0%16,94915,13715,24912,2173,36573,16915,999-11,424-3,53221,85012,172-9,569-106,90520,93331,717---
Cashflow From Financing-9114.3%-1,935-21.00-213-15.00-458-11,601-42.00-51482,232229-2,378433167,115-531-2,584---
  Buy Backs-73.9%12.0046.00217-17.0045.00------------

AFIB Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Statement of Comprehensive Income [Abstract]    
Revenue$ 5,238$ 3,644$ 14,696$ 11,401
Cost of products sold8,5956,95123,44723,589
Gross profit(3,357)(3,307)(8,751)(12,188)
Operating expenses (income):    
Research and development4,7955,94617,71221,884
Selling, general and administrative7,4329,67926,28038,207
Goodwill impairment00012,026
Restructuring01,3314752,280
Change in fair value of contingent consideration01981231,153
Gain on sale of business(2,648)0(5,927)(43,575)
Total operating expenses9,57917,15438,66331,975
Loss from operations(12,936)(20,461)(47,414)(44,163)
Other income (expense):    
Loss on debt extinguishment000(7,947)
Change in fair value of warrant liability6369041,478904
Interest income5472412,223292
Interest expense(1,409)(1,109)(4,110)(3,810)
Total other income (expense), net(226)36(409)(10,561)
Loss before income taxes(13,162)(20,425)(47,823)(54,724)
Income tax expense750750
Net loss(13,237)(20,425)(47,898)(54,724)
Other comprehensive income (loss)    
Unrealized gain on marketable securities43970
Foreign currency translation adjustment(66)(351)(91)(904)
Comprehensive loss$ (13,299)$ (20,737)$ (47,982)$ (55,628)
Net loss per common share, basic (in dollars per share)$ (0.45)$ (0.72)$ (1.65)$ (1.93)
Net loss per common share, diluted (in dollars per share)$ (0.45)$ (0.72)$ (1.65)$ (1.93)
Weighted average shares outstanding, basic (in shares)29,262,76828,359,51629,024,35328,273,207
Weighted average shares outstanding, diluted (in shares)29,262,76828,359,51629,024,35328,273,207

AFIB Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 24,100$ 25,584
Marketable securities, short-term14,37544,863
Restricted cash, short-term7,0155,764
Accounts receivable8,95221,085
Inventory15,72813,327
Employer retention credit receivable04,703
Prepaid expenses and other current assets2,4672,541
Total current assets72,637117,867
Noncurrent assets  
Property and equipment, net6,6119,221
Right-of-use assets, net3,3593,872
Intangible assets, net1,4331,583
Other assets688897
Total assets84,728133,440
Current liabilities:  
Accounts payable4,7544,721
Accrued liabilities7,4389,686
Contingent consideration, short-term01,800
Operating lease liabilities, short-term707319
Warrant liability1,8683,346
Total current liabilities14,76719,872
Operating lease liabilities, long-term3,4624,103
Long-term debt34,76134,434
Other long-term liabilities3212
Total liabilities53,02258,421
Commitments and contingencies (Note 12)
Stockholders' equity  
Preferred stock, $0.001 par value; 5,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 6,666 shares of the preferred stock, designated as Series A Common Equivalent Preferred Stock, are issued and outstanding as of September 30, 2023 and December 31, 202200
Common stock, $0.001 par value; 260,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 29,289,934 and 28,554,656 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively2929
Additional paid-in capital598,842594,173
Accumulated deficit(566,212)(518,314)
Accumulated other comprehensive loss(953)(869)
Total stockholders' equity31,70675,019
Total liabilities and stockholders' equity$ 84,728$ 133,440
AFIB
Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. The company was incorporated in 2011 and is headquartered in Carlsbad, California.
 CEO
 WEBSITEwww.acutusmedical.com
 EMPLOYEES225

Acutus Medical, Inc. Frequently Asked Questions


What is the ticker symbol for Acutus Medical, Inc.? What does AFIB stand for in stocks?

AFIB is the stock ticker symbol of Acutus Medical, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Acutus Medical, Inc. (AFIB)?

As of Tue Feb 20 2024, market cap of Acutus Medical, Inc. is 7.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AFIB stock?

You can check AFIB's fair value in chart for subscribers.

What is the fair value of AFIB stock?

You can check AFIB's fair value in chart for subscribers. The fair value of Acutus Medical, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Acutus Medical, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AFIB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Acutus Medical, Inc. a good stock to buy?

The fair value guage provides a quick view whether AFIB is over valued or under valued. Whether Acutus Medical, Inc. is cheap or expensive depends on the assumptions which impact Acutus Medical, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AFIB.

What is Acutus Medical, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Feb 20 2024, AFIB's PE ratio (Price to Earnings) is -0.21 and Price to Sales (PS) ratio is 0.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AFIB PE ratio will change depending on the future growth rate expectations of investors.